Kaken Pharmaceutical will hand Alumis $40 million in the near term for the rights to develop a late-stage tyrosine kinase 2 (TYK2) inhibitor as a dermatology treatment in Japan. The drug in ...

Faculty for Biochemistry and Molecular Medicine & Biocenter Oulu, University of Oulu, Aapistie 7, 90220 Oulu, Finland ...

About Stenoparib Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging ...

Get Instant Summarized Text (Gist) New inhibitors of the enzyme human 15-lipoxygenase-2 (h15-LOX-2) have been identified using computational tools and virtual screening. This enzyme is involved in ...

State Key Laboratory of Bioactive Molecules and Druggability Assessment, Guangdong Basic Research Center of Excellence for Natural Bioactive Molecules and Discovery of Innovative Drugs, International ...

The trial focused on stenoparib, a novel dual PARP/Wnt pathway inhibitor, and its effectiveness ... the drug’s dual action on both PARP and Tankyrase targets and its potential for durable ...

The poster presentation, titled "A Phase II Trial of Stenoparib (2X-121): A Novel Dual Tankyrase and PARP Inhibitor in Advanced, Recurrent Ovarian Cancer," will be presented by Dr. Fernanda B.

Janus kinase inhibitors (JAKis) are an important treatment option for people with chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, Crohn's disease or ulcerative colitis.

About Stenoparib Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging ...

Stenoparib is a dual-targeted inhibitor of PARP1/2 and tankyrase 1/2, developed for cancer treatment, particularly advanced ovarian cancer. How much is the civil penalty Allarity agreed to pay?